AVROBIO(AVRO) - 2024 Q3 - Quarterly Report

Financial Performance - The company reported net losses of $17.7 million for Q3 2024, compared to$10.1 million for Q3 2023, and $45.6 million for the nine months ended September 30, 2024, compared to$35.0 million for the same period in 2023[63]. - Net loss for Q3 2024 was $17.7 million, a 76$10.1 million in Q3 2023[75]. - Net cash used in operating activities was $42.3 million for the nine months ended September 30, 2024, compared to$29.0 million in 2023[85]. - The company does not expect to generate revenue from product sales in the foreseeable future and will need substantial additional funding to support ongoing operations[68]. Cash and Funding - As of September 30, 2024, the company had an accumulated deficit of $136.2 million and cash and cash equivalents of$159.1 million, which is expected to fund operations for at least the next twelve months[61]. - The company has raised an aggregate of $288.6 million since inception through various financing methods, including the sale of convertible preferred stock and common stock[61]. - Net cash provided by financing activities was$172.8 million for the nine months ended September 30, 2024, primarily from the sale of shares and proceeds from the Merger[89]. - The company anticipates needing additional capital to fund ongoing operations and research and development activities[84]. Expenses - Research and development expenses increased by 76% to $14.3 million in Q3 2024 from$8.1 million in Q3 2023[75]. - General and administrative expenses rose by 169% to $5.3 million in Q3 2024 compared to$2.0 million in Q3 2023[78]. - Total operating expenses for Q3 2024 were $19.6 million, a 94$10.1 million in Q3 2023[75]. - General and administrative expenses for the nine months ended September 30, 2024, were $11.8 million, a 115$5.5 million in the same period of 2023[79]. Clinical Trials and Development - The Phase 1a trial for the lead asset TX45 showed favorable results, with no severe adverse events and a favorable pharmacokinetic/pharmacodynamic relationship[61]. - The Phase 1b hemodynamic clinical trial for TX45 is enrolling ahead of plan, with topline results expected in late Q1 or early Q2 2025[61]. - The APEX Phase 2 clinical trial for TX45 commenced in October 2024, with topline results anticipated in 2026[61]. - The company plans to initiate a Phase 1 clinical trial for TX2100 in Q4 2025 or Q1 2026, pending IND enabling studies[61]. Merger and Financing - The merger with AVROBIO was completed on June 20, 2024, resulting in Legacy Tectonic securityholders owning approximately 38.5% of the outstanding shares on a diluted basis[65]. - Concurrently with the merger, the company raised $96.6 million through a Subscription Agreement at a price of$12.40 per share[66]. - The company issued SAFEs for proceeds of $34.1 million in October and December 2023, recorded as liabilities at fair value[73]. Obligations and Commitments - As of September 30, 2024, the company's total contractual obligations and commitments amount to$3.788 million, with $2.163 million due within one year[92]. - The company has a one-time license fee obligation of$170,000 to Harvard, payable in equal installments over three years, with the final installment made in July 2024[94]. - The company is obligated to pay up to $8.5 million in milestone payments for products granted FDA marketing authorization under the Harvard License Agreement[94]. - The company has a license agreement with Alloy Therapeutics, which includes total milestone payments of$4.8 million and annual commercial payments in the low seven digits for the first six years of sales[95]. Interest Income and Financial Sensitivity - Interest income surged by 1,912% to $1.9 million in Q3 2024 from$97,000 in Q3 2023, primarily due to increased cash and cash equivalents[75]. - Interest income increased by $2.0 million for the nine months ended September 30, 2024, primarily due to an increase in cash and cash equivalents resulting from the Merger[83]. - The company’s financial condition is sensitive to interest rate changes, but a 10% change in market interest rates would not materially affect the fair market value of its investment portfolio[102].